A detailed history of Ubs Group Ag transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 240,113 shares of VIR stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
240,113
Previous 383,188 37.34%
Holding current value
$1.67 Million
Previous $2.87 Million 38.61%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$6.74 - $10.17 $964,325 - $1.46 Million
-143,075 Reduced 37.34%
240,113 $1.76 Million
Q3 2024

Nov 14, 2024

BUY
$7.26 - $10.7 $651,316 - $959,929
89,713 Added 30.57%
383,188 $2.87 Million
Q2 2024

Aug 13, 2024

SELL
$7.63 - $12.66 $1.32 Million - $2.19 Million
-172,733 Reduced 37.05%
293,475 $2.61 Million
Q1 2024

May 13, 2024

SELL
$8.6 - $11.9 $515,759 - $713,666
-59,972 Reduced 11.4%
466,208 $4.72 Million
Q4 2023

Feb 09, 2024

BUY
$7.76 - $10.29 $1.87 Million - $2.48 Million
240,648 Added 84.28%
526,180 $5.29 Million
Q3 2023

Nov 09, 2023

BUY
$9.14 - $24.62 $682,794 - $1.84 Million
74,704 Added 35.43%
285,532 $2.68 Million
Q2 2023

Aug 11, 2023

BUY
$23.2 - $27.29 $2.06 Million - $2.42 Million
88,702 Added 72.63%
210,828 $5.17 Million
Q1 2023

May 12, 2023

SELL
$22.26 - $30.85 $3.73 Million - $5.17 Million
-167,601 Reduced 57.85%
122,126 $2.84 Million
Q4 2022

Feb 08, 2023

BUY
$19.96 - $28.22 $3.7 Million - $5.23 Million
185,199 Added 177.18%
289,727 $7.33 Million
Q3 2022

Nov 10, 2022

SELL
$18.26 - $31.1 $408,056 - $694,991
-22,347 Reduced 17.61%
104,528 $2.02 Million
Q2 2022

Aug 10, 2022

SELL
$19.08 - $26.7 $3.7 Million - $5.18 Million
-194,178 Reduced 60.48%
126,875 $3.23 Million
Q1 2022

May 16, 2022

BUY
$21.19 - $40.01 $4.78 Million - $9.02 Million
225,346 Added 235.45%
321,053 $8.26 Million
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $2.33 Million - $4.07 Million
75,375 Added 370.72%
95,707 $4.01 Million
Q3 2021

Nov 15, 2021

SELL
$34.9 - $54.54 $50,919 - $79,573
-1,459 Reduced 6.7%
20,332 $884,000
Q2 2021

Aug 13, 2021

SELL
$38.75 - $51.0 $510,918 - $672,435
-13,185 Reduced 37.7%
21,791 $1.03 Million
Q1 2021

May 12, 2021

SELL
$26.34 - $83.07 $276,965 - $873,481
-10,515 Reduced 23.11%
34,976 $1.79 Million
Q4 2020

Feb 11, 2021

SELL
$25.51 - $43.38 $508,414 - $864,563
-19,930 Reduced 30.46%
45,491 $1.22 Million
Q3 2020

Nov 12, 2020

BUY
$28.28 - $53.6 $791,642 - $1.5 Million
27,993 Added 74.79%
65,421 $2.25 Million
Q2 2020

Jul 31, 2020

BUY
$27.89 - $47.86 $927,091 - $1.59 Million
33,241 Added 793.91%
37,428 $1.53 Million
Q1 2020

May 01, 2020

SELL
$12.04 - $60.2 $93,550 - $467,754
-7,770 Reduced 64.98%
4,187 $143,000
Q4 2019

Feb 14, 2020

BUY
$11.83 - $15.85 $141,451 - $189,518
11,957 New
11,957 $150,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $922M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.